Search Results

You are looking at 1 - 1 of 1 items for

  • Author: P. Koen Bos x
Clear All Modify Search
Stijn E. W. Geraets Department of Orthopaedics, Erasmus MC, University Medical Centre Rotterdam, Rotterdam, The Netherlands

Search for other papers by Stijn E. W. Geraets in
Google Scholar
PubMed
Close
,
P. Koen Bos Department of Orthopaedics, Erasmus MC, University Medical Centre Rotterdam, Rotterdam, The Netherlands

Search for other papers by P. Koen Bos in
Google Scholar
PubMed
Close
, and
Johan van der Stok Department of Orthopaedics, Erasmus MC, University Medical Centre Rotterdam, Rotterdam, The Netherlands

Search for other papers by Johan van der Stok in
Google Scholar
PubMed
Close

  • Surgery of long bone metastases is associated with a significant risk of perioperative blood loss, which may necessitate blood transfusion.

  • Successful embolization (> 70% obliteration of vascularity) can be achieved in 36–75% of cases.

  • The reported rate of embolization-related complications is 0–9%.

  • Three out of six level III evidence studies showed a reduction in perioperative blood loss and/or blood transfusion requirement after preoperative embolization of renal cell carcinoma metastasis in long bones; three out of six studies did not.

  • One level III evidence study did not show a reduction in perioperative blood loss and/or transfusion requirement after preoperative embolization of hepatocellular carcinoma metastases in long bones.

  • There were no studies found that support preoperative embolization of thyroid metastases or other frequent long bone metastases (e.g. mamma carcinoma, lung carcinoma, or prostate carcinoma).

  • The clinical level of evidence of the studies found is low and randomized studies taking into account primary tumour, location of metastases and type of surgery are therefore desired.

Cite this article: EFORT Open Rev 2020;5:17-25. DOI: 10.1302/2058-5241.5.190013

Open access